Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

This study is testing a combination of three drugs — tazemetostat (an epigenetic therapy), zanubrutinib (a targeted BTK inhibitor), and an anti-CD20 antibody (like rituximab or obinutuzumab) — for people with follicular lymphoma or other B-cell lymphomas that have relapsed or are difficult to treat. **You may be eligible if...** - You are 18 or older - You have follicular lymphoma or another B-cell lymphoma that has relapsed or not responded to prior treatment - You have received at least one prior therapy - You are in acceptable health (ECOG score 0–2) - Your organ function is within acceptable ranges **You may NOT be eligible if...** - You have active central nervous system lymphoma - You require anticoagulant therapy that may interact with study drugs - You have active autoimmune disease - You are pregnant or breastfeeding - You have a history of severe reactions to anti-CD20 therapy Talk to your doctor to see if this trial is right for you.